Equities

Nautilus Biotechnology Inc

NAUT:NSQ

Nautilus Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.44
  • Today's Change0.06 / 2.52%
  • Shares traded55.73k
  • 1 Year change-14.98%
  • Beta1.0081
Data delayed at least 15 minutes, as of Nov 22 2024 20:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments173184346
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.422.743.49
Other current assets, total------
Total current assets177187349
Property, plant & equipment, net373332
Goodwill, net------
Intangibles, net------
Long term investments9112916
Note receivable - long term------
Other long term assets0.180.150.16
Total assets306350398
LIABILITIES
Accounts payable1.641.271.72
Accrued expenses7.485.524.09
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities9.126.795.81
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total312829
Total liabilities403535
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital468455444
Retained earnings (accumulated deficit)(202)(139)(81)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.26)(1.85)(0.18)
Total equity265315364
Total liabilities & shareholders' equity306350398
Total common shares outstanding125125124
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.